Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXUS: ANXV in NPDR and RVO
NCT07259928Phase 2Recruiting
- Sponsor
- Annexin Pharmaceuticals AB
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of annexin a5 in retinal vein occlusion (RVO), sponsored by Annexin Pharmaceuticals AB. Started Nov 2025; status: recruiting.
02
Drugs
annexin a5
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT07259928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259928.